Welcome to our dedicated page for Horizon Therapeutics Pub L news (Ticker: HZNP), a resource for investors and traders seeking the latest updates and insights on Horizon Therapeutics Pub L stock.
Horizon Therapeutics plc (NASDAQ: HZNP) is a global biotechnology leader focused on developing therapies for rare, autoimmune, and severe inflammatory diseases. This dedicated news hub provides investors and healthcare professionals with timely updates on regulatory milestones, research breakthroughs, and strategic corporate initiatives shaping the company's trajectory.
Access authoritative information on Horizon's innovative treatments like TEPEZZA® and KRYSTEXXA®, along with analysis of key developments including partnership announcements and regulatory filings. Our curated news collection serves as your primary resource for understanding Horizon's position in the biopharmaceutical landscape and its commitment to addressing unmet medical needs.
Key updates cover clinical trial progress, FDA communications, financial results, and major corporate events such as Horizon's pending acquisition by Amgen following FTC clearance. All content is sourced from official releases and verified channels to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to Horizon Therapeutics' evolving story. For additional context on the company's mission and pipeline, visit their official website at HorizonTherapeutics.com.
Horizon Therapeutics (NASDAQ: HZNP) announced that Dara Mann, VP of marketing for ophthalmology, was named a 2022 Rising Star by the Healthcare Businesswomen’s Association. Mann has over 15 years of experience and has been pivotal in launching innovative therapies, including TEPEZZA. This recognition highlights her contributions to increasing awareness and accessibility of treatments among patients and healthcare providers, especially during challenging times like the pandemic. Horizon continues to focus on developing medicines for rare and severe diseases.
Horizon Therapeutics plc (NASDAQ: HZNP) launches a nationwide campaign for Mental Health Awareness Month, partnering with Lori Gottlieb to address the emotional challenges of Thyroid Eye Disease (TED). The 'Dear TED' initiative encourages individuals with TED to share their experiences through letters, fostering connection and support. With 42% of TED patients reporting anxiety and depression, the campaign provides resources, including a podcast and personal stories, aiming to empower patients to manage their condition and seek timely care. For more, visit DearTEDLetters.com.
Horizon Therapeutics (Nasdaq: HZNP) has entered a multi-year partnership to become the official biotech partner of the Chicago Sky. This collaboration involves community initiatives, including the newly launched Chicago Sky Basketball Academy and contributions to the Beyond Basketball social justice program. Horizon aims to enhance economic development, youth financial literacy, and address food deserts. With existing partnerships with the Chicago Cubs, Bulls, and Bears, this initiative underscores Horizon's commitment to community engagement.
Horizon Therapeutics reported Q1 2022 net sales of $885.2 million, a 159% increase year-over-year, driven largely by TEPEZZA and KRYSTEXXA. GAAP net income reached $204.3 million, with adjusted EBITDA at $371.2 million. The company maintains its full-year guidance for 2022 net sales between $3.9 billion and $4.0 billion, reflecting a 22% growth. TEPEZZA sales are expected to grow in the mid-30s percentage, while KRYSTEXXA is forecasted for over 20% growth. The FDA granted priority review for the co-treatment of KRYSTEXXA with methotrexate, highlighting further growth potential.
Horizon Therapeutics (NASDAQ: HZNP) announced that its Phase 2 clinical trial for dazodalibep (HZN-4920) in rheumatoid arthritis successfully met its primary endpoint. The trial involved approximately 75 subjects with moderate-to-severe RA and showed a significant change in disease activity as measured by DAS28-CRP. Dazodalibep was well tolerated, and the results indicate potential for addressing a critical pathway in autoimmune diseases. Detailed results will be shared at an upcoming medical congress.
Horizon Therapeutics plc (Nasdaq: HZNP) has launched the #RAREis Global Advocate Grant, aimed at supporting patient advocacy groups in the rare disease community. This initiative will provide financial assistance of
Horizon Therapeutics has received European Commission approval for UPLIZNA (inebilizumab) as monotherapy for adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are AQP4-IgG+. This medication, the first targeted CD19+ B-cell-depleting therapy approved in the EU for NMOSD, showed significant efficacy in the pivotal N-MOmentum trial, where 87.6% of treated patients remained attack-free for 28 weeks. With approximately 7,300 NMOSD patients in Europe, the approval provides new hope for effective treatment amidst the severe impacts of this disease.
Horizon Therapeutics plc (Nasdaq: HZNP) launched the second annual global innovation challenge, The Horizon Prize, to address challenges faced by over 400 million individuals living with rare diseases. This year's question focuses on enhancing the quality of life for these patients. Up to two winners will receive a total of $150,000 in funding. Past winners developed solutions to improve access to care. The initiative aims to inspire global innovators to create impactful solutions that empower patients and improve healthcare accessibility.
Horizon Therapeutics plc (Nasdaq: HZNP) will release its first-quarter 2022 financial results on May 4, 2022, at 8 a.m. Eastern Time. A live webcast will follow the announcement, allowing management to review financial and operational results. Investors can access the webcast at ir.horizontherapeutics.com, with a replay available two hours post-event. Horizon is dedicated to developing medications for rare, autoimmune, and severe inflammatory diseases, focusing on clinically meaningful therapies.
